Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 6:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 271 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: COVID-19 Severe Pneumonia Clear all
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Efficacy and Safety of NVX-CoV2705

NCT07086222
View directory record Official record
Conditions
COVID-19, Sars-CoV-2 Infection
Interventions
NVX-CoV2705, Placebo
Biological
Lead sponsor
Novavax
Industry
Eligibility
50 Years to 65 Years
Enrollment
6,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
99
States / cities
Athens, Alabama • Birmingham, Alabama • Gadsden, Alabama + 88 more
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 22, 2026, 6:45 AM EDT
Active, not recruiting No phase listed Observational

A Study to Look at the Health Outcomes of Patients With COVID-19 and Influenza

NCT05160636
View directory record Official record
Conditions
COVID-19, Coronavirus Disease 2019, Influenza
Interventions
COVID-19 Vaccine
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
999 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 22, 2026, 6:45 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2

NCT04611802
View directory record Official record
Conditions
SARS-CoV Infection, Covid19
Interventions
SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period), Placebo (Initial Vaccination Period), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Crossover Vaccination period), Placebo (Crossover Vaccination period), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Booster Vaccination), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Second Booster Vaccination)
Biological · Other
Lead sponsor
Novavax
Industry
Eligibility
12 Years and older
Enrollment
33,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
144
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tempe, Arizona + 110 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2023 · Synced Oct 22, 2026, 6:45 AM EDT
Recruiting Phase 3 Interventional

Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen

NCT05624450
View directory record Official record
Conditions
Viral Lung Infection and Acute Respiratory Failure
Interventions
Tozorakimab, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
3,527 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
75
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 22, 2026, 6:45 AM EDT
Completed No phase listed Observational

Predictors of Severe COVID-19 Outcomes

NCT04388813
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, COVID-19
Interventions
Not listed
Lead sponsor
Verily Life Sciences LLC
Industry
Eligibility
18 Years and older
Enrollment
494 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
8
States / cities
Tucson, Arizona • Los Angeles, California • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated May 28, 2024 · Synced Oct 22, 2026, 6:45 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

COVID-19 Testing Sample Acquisition Throughput and Efficiency

NCT04532411
View directory record Official record
Conditions
SARS-CoV Infection, Respiratory Viral Infection, Personal Protective Equipment, Covid19
Interventions
Personal Protective Testing Booth
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
Not listed
Enrollment
28,948 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 23, 2023 · Synced Oct 22, 2026, 6:45 AM EDT
Terminated Phase 2 Interventional Results available

Antithrombin III in Infectious Disease Caused by COVID-19

NCT04899232
View directory record Official record
Conditions
Antithrombin III Deficiency, Covid19
Interventions
Antithrombin III
Drug
Lead sponsor
Enrique Ginzburg
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 7, 2022 · Synced Oct 22, 2026, 6:45 AM EDT
Terminated Phase 1Phase 2 Interventional

RAPA-501-Allo Therapy of COVID-19-ARDS

NCT04482699
View directory record Official record
Conditions
Severe COVID-19 Disease
Interventions
RAPA-501-Allo off-the-shelf Therapy of COVID-19, Placebo
Biological · Other
Lead sponsor
Rapa Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 11, 2021 · Synced Oct 22, 2026, 6:45 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Oral Rinse to Reduced Expelled Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) During COVID-19 Infection

NCT04931004
View directory record Official record
Conditions
Covid19
Interventions
Mouthwash Product
Drug
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Newark, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 30, 2026 · Synced Oct 22, 2026, 6:45 AM EDT
Completed No phase listed Observational

A Clinical Evaluation of Pine Trees Health Test System Including the Pine Trees Health Reader and COVID-19 Test for Point-of-Care

NCT05107258
View directory record Official record
Conditions
SARS (Severe Acute Respiratory Syndrome), Covid19
Interventions
The Pine Trees Health Test System
Diagnostic Test
Lead sponsor
Pine Trees, Inc.
Industry
Eligibility
6 Years and older
Enrollment
195 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
3
States / cities
Spring Hill, Florida • Statesville, North Carolina • Redmond, Washington
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 22, 2026, 6:45 AM EDT
Completed Phase 3 Interventional Results available

MP0420 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

NCT05780463
View directory record Official record
Conditions
COVID-19
Interventions
MP0420, Placebo, Remdesivir
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
485 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
73
States / cities
Tucson, Arizona • Chula Vista, California • Fresno, California + 52 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2024 · Synced Oct 22, 2026, 6:45 AM EDT
Completed Phase 2 Interventional Results available

Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease

NCT04376684
View directory record Official record
Conditions
Severe Acute Respiratory Syndrome
Interventions
Otilimab, Placebo 1, Placebo 2, Standard of care
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
1,156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
21
States / cities
Mobile, Alabama • Little Rock, Arkansas • Sacramento, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2024 · Synced Oct 22, 2026, 6:45 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Study of the Efficacy and Safety of Intravenous Pamrevlumab, in Hospitalized Participants With Acute COVID-19 Disease

NCT04432298
View directory record Official record
Conditions
COVID-19
Interventions
Pamrevlumab, Placebo
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
40 Years to 85 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
4
States / cities
Detroit, Michigan • Greensboro, North Carolina • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 18, 2022 · Synced Oct 22, 2026, 6:45 AM EDT
Completed No phase listed Observational

COVID-19: Pediatric Research Immune Network on SARS-CoV-2 and MIS-C

NCT04588363
View directory record Official record
Conditions
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), Multisystem Inflammatory Syndrome in Children (MIS-C), Coronavirus Disease 2019 (COVID-19)
Interventions
SARS-CoV-2 and/or MIS-C Exposure
Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 20 Years
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
20
States / cities
Loma Linda, California • Los Angeles, California • Palo Alto, California + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 29, 2024 · Synced Oct 22, 2026, 6:45 AM EDT
Completed Phase 2 Interventional Results available

A Trial of Aclaris Therapeutics, Inc. (ATI)-450 in Patients With Moderate-severe Novel Coronavirus Disease 2019 (COVID-19)

NCT04481685
View directory record Official record
Conditions
Covid19
Interventions
ATI-450, Placebo
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Oct 22, 2026, 6:45 AM EDT
Terminated Phase 2 Interventional Results available

COVID-19 Administration of Single-Dose Subcutaneous Anti- Spike(s) SARS-CoV-2 Monoclonal Antibodies Casirivimab and Imdevimab in High-Risk Pediatric Participants Under 12 Years of Age

NCT04992273
View directory record Official record
Conditions
COVID-19
Interventions
casirivimab+imdevimab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
1 Minute to 12 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
7
States / cities
Anaheim, California • Miami, Florida • Stony Brook, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 22, 2026, 6:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Food Effect Study to Evaluate the Effect of High-Fat Meal on the Relative Bioavailability of PF-07321332 Boosted With Ritonavir in Healthy Adult Participants

NCT05129475
View directory record Official record
Conditions
Healthy Participants
Interventions
PF-07321332/ritonavir, Ritonavir
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 5, 2023 · Synced Oct 22, 2026, 6:45 AM EDT
Terminated Phase 2Phase 3 Interventional Results available

Treatment of Severe Coronavirus Disease 2019 (COVID-19) With Convalescent Plasma

NCT04502472
View directory record Official record
Conditions
Covid-19
Interventions
Convalescent plasma transfusion
Biological
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 10, 2022 · Synced Oct 22, 2026, 6:45 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Beaumont Health Large-scale Automated Serologic Testing for COVID-19

NCT04349202
View directory record Official record
Conditions
COVID-19, Coronavirus Infection, Severe Acute Respiratory Syndrome Coronavirus 2
Interventions
EUROIMMUN assay
Diagnostic Test
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years and older
Enrollment
20,614 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
2
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 5, 2021 · Synced Oct 22, 2026, 6:45 AM EDT
Completed Phase 1 Interventional Results available

COVID-19 Convalescent Plasma for the Treatment of Hospitalized Patients With Pneumonia Caused by SARS-CoV-2.

NCT04397757
View directory record Official record
Conditions
COVID-19
Interventions
COVID-19 Convalescent Plasma
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 19, 2022 · Synced Oct 22, 2026, 6:45 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for Hospitalized Adult Patients With COVID-19

NCT04426695
View directory record Official record
Conditions
COVID-19
Interventions
REGN10933+REGN10987 combination therapy, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
2,252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
96
States / cities
Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 70 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2023 · Synced Oct 22, 2026, 6:45 AM EDT
Recruiting No phase listed Observational

Determinants of SARS (Severe Acute Respiratory Syndrome)-COV2 (COVID-19) Persistence After Convalescence

NCT04448145
View directory record Official record
Conditions
COVID-19, Corona Virus Infection, SARS-CoV 2
Interventions
Not listed
Lead sponsor
Columbia University
Other
Eligibility
7 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 22, 2026, 6:45 AM EDT
Completed Phase 3 Interventional Results available

VIR-7831 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)

NCT05780281
View directory record Official record
Conditions
COVID-19
Interventions
VIR-7831, Placebo, Remdesivir
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
367 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
74
States / cities
Tucson, Arizona • Fresno, California • Loma Linda, California + 50 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2023 · Synced Oct 22, 2026, 6:45 AM EDT
Recruiting Phase 3 Interventional

A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)

NCT06667700
View directory record Official record
Conditions
Coronavirus Disease (COVID-19)
Interventions
Molnupiravir, Placebo
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
3,082 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
71
States / cities
Cullman, Alabama • Paradise Valley, Arizona • Phoenix, Arizona + 58 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 22, 2026, 6:45 AM EDT